Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
- PMID: 15540402
- DOI: 10.12927/hcq.2004.17236
Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
Abstract
Background: Public prescription drug plans vary markedly across Canada. To address perceived inequities in coverage across provinces, the February 2003 First Ministers' Accord on Health Care Renewal committed to ensuring that all Canadians have reasonable access to catastrophic drug coverage. A national standard for "reasonable" catastrophic coverage has yet to be formally defined.
Objective: To compare the private financial burdens from prescription drugs that Canadian households would face if each of the current provincial pharmacare models were adopted as the national standard.
Methods: Through simulation modelling, we computed household private financial burden by applying the cost-sharing rules from provincial drug plans to a nationally representative set of 4,860 household types differing in size, age composition, income and drug expense levels. The proportions of households that would face private out-of-pocket payments exceeding critical, or catastrophic, percentages of household income were calculated.
Results: Private financial burden due to prescription drug costs varies considerably across provincial pharmacare models. Comprehensive, tax-financed pharmacare models that limit out-of-pocket expenditures to a given percentage of income, such as those found in British Columbia, Saskatchewan, Manitoba and Ontario, provide the greatest protection against catastrophic prescription drug costs. There appears, however, to be no "gold standard" for an acceptable financial burden to be borne by patients.
Similar articles
-
Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.Open Med. 2011;5(1):e1-9. Epub 2011 Jan 4. Open Med. 2011. PMID: 22046212 Free PMC article.
-
Policy choices for pharmacare; the need to examine benefit design, medication management strategies and evaluation.Healthc Pap. 2004;4(3):36-45; discussion 68-72. doi: 10.12927/hcpap..16875. Healthc Pap. 2004. PMID: 15114068
-
Post-Romanow pharmacare: last-dollar first...first-dollar lost?Healthc Pap. 2004;4(3):10-20. doi: 10.12927/hcpap..16871. Healthc Pap. 2004. PMID: 15114064
-
Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018. J Pharm Policy Pract. 2018. PMID: 30443371 Free PMC article. Review.
-
Pharmacare in Canada: The paediatric perspective.Paediatr Child Health. 2020 Mar;25(2):113-124. doi: 10.1093/pch/pxz176. Epub 2020 Mar 13. Paediatr Child Health. 2020. PMID: 32189975 Free PMC article. Review.
Cited by
-
Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.CMAJ. 2008 Feb 12;178(4):405-9. doi: 10.1503/cmaj.070587. CMAJ. 2008. PMID: 18268266 Free PMC article.
-
The born identity: prescription drug coverage by eligibility group.Can Fam Physician. 2011 Sep;57(9):1016-8. Can Fam Physician. 2011. PMID: 21918145 Free PMC article. No abstract available.
-
Income-based drug coverage in british columbia: towards an understanding of the policy.Healthc Policy. 2006 Nov;2(2):92-108. Healthc Policy. 2006. PMID: 19305707 Free PMC article.
-
Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.Open Med. 2011;5(1):e1-9. Epub 2011 Jan 4. Open Med. 2011. PMID: 22046212 Free PMC article.
-
Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.CMAJ Open. 2017 Nov 22;5(4):E808-E813. doi: 10.9778/cmajo.20170065. CMAJ Open. 2017. PMID: 29180377 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources